Back to top

Analyst Blog

Following the announcement of its decision to buy Amil Participações S.A of Brazil, all the leading rating agencies – A.M.Best Co., Moody’s Corp. (MCO - Analyst Report), Standard and Poor’s as well as Fitch ratings – have taken rating action on UnitedHealth Group Inc. (UNH - Analyst Report).

A.M. Best has kept the financial strength rating (“FSR”), issuer credit ratings (“ICR”) and issuer debt ratings (“IDR”) unchanged for UnitedHealth as well as its subsidiaries at the current levels. Though the company will witness an increase in its debt ratio due to the acquisition, the rating agency is of the view that the increased leverage level as well as the interest coverage ratio will support its current ratings.

The rating agency is confident of the company’s ability to eventually cut down its debt level by deploying money for share repurchases.

A.M. Best is positive about the abovementioned acquisition, which will position the company as a leading insurer in Brazil, one of the fastest emerging economies of the world. Though at the initial level, the acquisition will only be slightly accretive to the company’s cash flow, huge synergies can be reaped eventually.

Moody’s has also affirmed UnitedHealth’s senior debt rating at ‘A3’ and the insurance financial strength (“IFS”) rating of UnitedHealthcare Insurance Company (UHIC) at A1. It has, however, lowered the outlook to negative from stable, reflecting concerns about the rise in leverage ratio attributable to the acquisition.  

Standard and Poor’s maintained its existing rating and outlook. In its view, the acquisition marks a giant step by UnitedHealth to diversify its operations internationally and it will result into long-term growth. It is also confident of the company’s ability to successfully integrate the acquisition given its past track record.

Another rating agency, Fitch Ratings also affirmed ‘A’ rating to the company’s long-term IDR and the 'A-' to senior unsecured securities.  It also kept its stable outlook intact. Fitch is of the opinion that the company’s debt and interest servicing capabilities will remain strong enough and will commensurate with the current levels. It is however, concerned with the integration risk relating to the acquisition as it views this large international purchase as one of its kind for the company.

Given UnitedHealth’s mammoth size and a very strong management team and a successful track record of successfully integrating businesses, we expect the same in case of the acquisition of Amil.  

UnitedHealth currently retains a Zacks #2 Rank, which translates into a short-term Buy rating. We are also maintaining our long-term Neutral recommendation on the shares.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%